Hemogenyx Pharmaceuticals Overview

  • Year Founded
  • 2012

Year Founded

  • Status
  • Public

  • Employees
  • 16

Employees

  • Stock Symbol
  • HEMO

Stock Symbol

  • Investments
  • 1

  • Share Price
  • $0.02
  • (As of Friday Closing)

Hemogenyx Pharmaceuticals General Information

Description

Hemogenyx Pharmaceuticals PLC is an operator of a biotechnology company intended to focus on the discovery, development, and commercialization of novel therapies and treatments for blood diseases, like leukaemia and lymphoma. The company's technologies aim to change the way in which bone marrow/hematopoietic stem cell transplants are performed and improve their efficacy, its three distinct products include an immunotherapy product for the treatment of relapsed/refractory acute myeloid leukaemia (AML) and patient conditioning, the bi-specific antibody, for the treatment of AML and a community-based rehabilitation/Biomedical engineering platform, enabling users to generate treatments for existing and emerging viral infections.

Contact Information

Formerly Known As
SILVER FALCON
Ownership Status
Publicly Held
Financing Status
Formerly VC-backed
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Stock Exchange
LON
Corporate Office
  • 6th Floor
  • 60 Gracechurch Street
  • London EC3V 0HR
  • England, United Kingdom

Hemogenyx Pharmaceuticals Timeline

2021202220232024
Financing RoundCaptured Employee CountEstimated Employee Growth

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Hemogenyx Pharmaceuticals Stock Performance

(As of Friday Closing)

Stock Price Previous Close 52 wk Range Market Cap Shares Average Volume EPS
$0.02 $0.02 $0.01 - $0.09 $25.1M 1.34B 11.5M

Hemogenyx Pharmaceuticals Financials Summary

In Thousands,
USD
TTM 31-Dec-2023 FY 2023 31-Dec-2023 FY 2022 31-Dec-2022 FY 2021 31-Dec-2021
EV 34,609 34,609 8,569 12,273
Revenue 0 0 0 0
EBITDA (7,235) (7,235) (4,686) (3,307)
Net Income (8,317) (8,317) (4,904) (7,012)
Total Assets 7,778 7,778 8,583 11,499
Total Debt 3,753 3,753 4,142 14
Public Fundamental Data provided by Morningstar, Inc. disclaimer

Hemogenyx Pharmaceuticals Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore Hemogenyx Pharmaceuticals‘s full profile, request access.

Request a free trial

Hemogenyx Pharmaceuticals Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion
Price
% Owned

This information is available in the PitchBook Platform. To explore Hemogenyx Pharmaceuticals‘s full profile, request access.

Request a free trial

Hemogenyx Pharmaceuticals Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Hemogenyx Pharmaceuticals PLC is an operator of a biotechnology company intended to focus on the discovery, development,
Drug Discovery
London, United Kingdom
16 As of 2023
000.00
000000000 000.00

000000

t ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exerci
0000 000000000
Abingdon, United Kingdom
00 As of 0000
000.00
000.00 0000-00-00
00000000000 000.00

000000

lor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut l
0000 000000000
London, United Kingdom
00 As of 0000
000.00
00000 0000-00-00
00000000000 000.00
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Hemogenyx Pharmaceuticals Competitors (4)

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Pathios Therapeutics Venture Capital-Backed Abingdon, United Kingdom 00 000.00 00000000000 000.00
Prokarium Venture Capital-Backed London, United Kingdom 00 000.00 00000000000 000.00
QuellTX Venture Capital-Backed London, United Kingdom 000 00000 00000000000 00000
Cabaletta Bio Formerly VC-backed Philadelphia, PA 000 00000 00000000 00000
To view Hemogenyx Pharmaceuticals’s complete competitors history, request access »

Hemogenyx Pharmaceuticals Executive Team (2)

Name Title Board Seat Contact Info
Vladislav Sandler Ph.D Co-Founder, Chief Executive Officer & Board Member
You’re viewing 1 of 2 executive team members. Get the full list »

Hemogenyx Pharmaceuticals Board Members (4)

Name Representing Role Since
Alexis Sandler JD Self Board Member 000 0000
Marc Feldmann Hemogenyx Pharmaceuticals Chairman & Board Member 000 0000
Peter Redmond Self Board Member 000 0000
Vladislav Sandler Ph.D Hemogenyx Pharmaceuticals Co-Founder, Chief Executive Officer & Board Member 000 0000
To view Hemogenyx Pharmaceuticals’s complete board members history, request access »

Hemogenyx Pharmaceuticals Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers

5.5k

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Hemogenyx Pharmaceuticals Investors

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info

This information is available in the PitchBook Platform. To explore Hemogenyx Pharmaceuticals‘s full profile, request access.

Request a free trial

Hemogenyx Pharmaceuticals Acquisitions (1)

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
Silver Falcon 08-Oct-2017 0000000000 Pharmaceuticals 000000000
To view Hemogenyx Pharmaceuticals’s complete acquisitions history, request access »

Hemogenyx Pharmaceuticals FAQs

  • When was Hemogenyx Pharmaceuticals founded?

    Hemogenyx Pharmaceuticals was founded in 2012.

  • Who is the founder of Hemogenyx Pharmaceuticals?

    Vladislav Sandler Ph.D is the founder of Hemogenyx Pharmaceuticals.

  • Who is the CEO of Hemogenyx Pharmaceuticals?

    Vladislav Sandler Ph.D is the CEO of Hemogenyx Pharmaceuticals.

  • Where is Hemogenyx Pharmaceuticals headquartered?

    Hemogenyx Pharmaceuticals is headquartered in London, United Kingdom.

  • What is the size of Hemogenyx Pharmaceuticals?

    Hemogenyx Pharmaceuticals has 16 total employees.

  • What industry is Hemogenyx Pharmaceuticals in?

    Hemogenyx Pharmaceuticals’s primary industry is Drug Discovery.

  • Is Hemogenyx Pharmaceuticals a private or public company?

    Hemogenyx Pharmaceuticals is a Public company.

  • What is Hemogenyx Pharmaceuticals’s stock symbol?

    The ticker symbol for Hemogenyx Pharmaceuticals is HEMO.

  • What is the current stock price of Hemogenyx Pharmaceuticals?

    As of 24-May-2024 the stock price of Hemogenyx Pharmaceuticals is $0.02.

  • What is the current market cap of Hemogenyx Pharmaceuticals?

    The current market capitalization of Hemogenyx Pharmaceuticals is $25.1M.

  • Who are Hemogenyx Pharmaceuticals’s competitors?

    Pathios Therapeutics, Prokarium, QuellTX, and Cabaletta Bio are competitors of Hemogenyx Pharmaceuticals.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read blog »
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process »